PFE.US Weekly · 2026-W37
Pfizer declined 2.56% to $27.72 this week, pressed by negative earnings and deteriorating profitability. Q2 EPS swung negative to -$0.0435 per share, down 109% sequentially from Q1, marking a multi-year low. Although weekly trading volume eased from prior week, valuation remains at historical highs while institutional ratings and capital flow signal divergence.
Price Action
Close of $27.72 vs prior Friday (Sept 4) close of $28.45, a weekly loss of $0.73 or -2.56%. Weekly trading range $27.42–$27.85, amplitude 1.56%, below the prior week’s peak of $29.21.
Daily average volume this week: 25.56 million shares, down 3.4% from the prior week. Versus the 60-day median of ~41.5 million shares, this week’s volume contracted. Turnover rate 0.45%, stable by recent standards—no extreme volume spike.
Intraweek pattern: consolidation at elevated levels. Monday (Sept 8) dipped to $27.79, mid-week traded $27.78–$27.65 with modest bounces, and closed Friday at $27.72. No decisive technical breakout or breakdown; high-level base-building tone.
Valuation & Earnings
Current P/E 36.45x sits at the 76th percentile of the 3-year range—a historically elevated level nearing the top of the range. P/B 1.85x; dividend yield (on $1.72 annual dividend) 6.2%, still competitive among large-cap pharma.
Latest quarter (Q2 2026) delivered a negative surprise: EPS -$0.0435 per share, down 109% sequentially from Q1’s +$0.4677 and down 108.5% year-over-year from Q2 2025’s +$0.5119. Worst single-quarter performance in recent history. Operating revenue $15.034 billion, up 2.6% YoY and up modestly from Q1’s $14.451 billion—growth momentum remains muted.
Net profit declined 108.5% to -$248 million. Operating income fell 8.3% sequentially to $4.191 billion (Q1 was $4.569 billion) but held roughly flat YoY (-0.31%). Q2 net margin turned negative at -1.65%, a sharp reversal from Q1’s +18.59%.
Consensus forecast for full-year EPS: $2.77 (latest snapshot). The Q2 miss of -$0.0435 creates a massive headwind for annual guidance realization.
Capital Flow
Capital shows retail inflow, institutional outflow—a divergence pattern. Retail (small): inflow $2,509 vs outflow $2,720, small net outflow. Mid-tier institutions: net outflow ~$65. Large players: net inflow ~$125.
Interpretation: major funds show modest buying interest, mid-tier funds flee, retail holds. Disagreement among market participants reflects uncertainty on near-term direction.
Institutional View
Current ratings: Buy 2, Strong Buy 8, Hold 16, Reduce 1. Coverage from 28 analysts. Bullish camp (Buy + Strong Buy) = 35.7%; Hold dominance = 57.1%. Reduce minimal at 3.6%. Low disagreement overall.
Price targets range $25.0–$35.75, median $28.875 (very close to current $27.72). Last update Sept 9, 2026, just 3 days old.
Caveat: ratings lag fundamental shifts. Broad bullishness masks the reality that few ratings have digested Q2’s severe miss. Expect material downgrade pressure in mid-to-late September.
Weekly News Highlights
Two themes dominated: Pfizer’s strategic partnerships and FDA vaccine approval.
- Pfizer climbs 1% to 52-week high after FDA OKs XFG COVID vaccine
- Pfizer gains 1% in premarket on FDA approval of XFG variant vaccine
- Weekly Recap | Pfizer +1.75%, FDA clears XFG variant vaccine
- Medicus Pharma signs co-development, licensing deal with Pfizer for CD228V antibody-drug conjugate
- Novartis India acquires Pfizer brands for $132m
- Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference | PFE Stock News
- Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot
- Pharmaceutical Stocks To Keep An Eye On - September 6th
- Pharmaceutical Stocks To Add to Your Watchlist - September 5th
- This is what I’d do with Pfizer stock right now
FDA clearance of an XFG variant COVID vaccine boosted Pfizer to a 52-week high early week. The CD228V ADC co-development pact signals pipeline depth in oncology. Yet these catalysts were completely offset by Friday’s Q2 earnings devastation, leaving the week at -2.56%.
Summary
Pfizer faces a stark contradiction: deteriorating fundamentals vs. bullish consensus ratings. Q2 EPS collapsed to negative, net margin swung to -1.65%, and full-year guidance faces severe headwinds—yet 28 of 28 analysts remain at Buy or Hold. Valuation at P/E 36.45x sits at a 3-year high while earnings contract; the gap invites correction.
Capital divergence (mid-tier and large institutions trimming, retail steadying) hints at confidence erosion beneath the surface. Product wins (vaccine, ADC partnerships) support long-term narrative but offer no offset to the current quarter’s damage. Watch for rating cuts and guidance revision in mid-September; that will reset market expectations.